相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients
Takao Takeshima et al.
JOURNAL OF HEADACHE AND PAIN (2022)
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2022)
The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates
Lars Jacob Stovner et al.
JOURNAL OF HEADACHE AND PAIN (2022)
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2022)
The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine
Simona Guerzoni et al.
NEUROLOGICAL SCIENCES (2022)
Deprescribing in migraine
Paolo Martelletti et al.
EXPERT OPINION ON DRUG SAFETY (2021)
Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
Todd J. Schwedt et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients
Raffaele Ornello et al.
PAIN AND THERAPY (2021)
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
Raffaele Ornello et al.
PAIN AND THERAPY (2021)
CGRP release in an experimental human trigeminal pain model
Achim Frese et al.
CEPHALALGIA (2021)
Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA
Enrique Martinez-Pias et al.
TOXINS (2021)
Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK
Georgia Hollier-Hann et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Short and Mid-Term Predictors of Response to OnabotulinumtoxinA: Real-Life Experience Observational Study
Alicia Alpuente et al.
HEADACHE (2020)
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
Rami Burstein et al.
HEADACHE (2020)
Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
Antonio Russo et al.
JOURNAL OF HEADACHE AND PAIN (2020)
A prospective real-world analysis of erenumab in refractory chronic migraine
Giorgio Lambru et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Combination therapy in migraine: asset or issue?
Paolo Martelletti
EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)
What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group
Simona Sacco et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2020)
Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine?
Rosaria Greco et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data
David W. Dodick et al.
CEPHALALGIA (2019)
CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA
R. Moreno-Mayordomo et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis
Peter J. Goadsby et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment
Francesca Schiano di Cola et al.
FRONTIERS IN NEUROLOGY (2019)
Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience
Fabrizio Vernieri et al.
HEADACHE (2019)
Prognosis Following Discontinuation of OnabotulinumA Therapy in Super-responding Chronic Migraine Patients
Jason Ching et al.
HEADACHE (2019)
Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine
Paul K. Winner et al.
HEADACHE (2019)
Migraine Epidemiology, Burden, and Comorbidity
Rebecca C. Burch et al.
NEUROLOGIC CLINICS (2019)
OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study
C. Dominguez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study
Clara Dominguez et al.
HEADACHE (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
James E. Frampton et al.
DRUGS (2018)
Unilateral pain and shorter duration of chronic migraine are significant predictors of response to onabotulinumtoxin A
C. Dominguez et al.
EUROPEAN JOURNAL OF NEUROLOGY (2018)
Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns
Daniela Buonvicino et al.
PAIN (2018)
Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
Lars Bendtsen et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
Todd Schwedt et al.
JOURNAL OF HEADACHE AND PAIN (2018)
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
Andrea Negro et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study
Mi Ji Lee et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2016)
OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine
Eva Cernuda-Morollon et al.
PAIN (2015)
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
Stephen D. Silberstein et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
CGRP and VIP Levels as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine
Eva Cernuda-Morollon et al.
HEADACHE (2014)
Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review
Michel Lanteri-Minet et al.
CEPHALALGIA (2011)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
Sheena K. Aurora et al.
HEADACHE (2011)
Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers
Milena De Felice et al.
BRAIN (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)